EQS-Adhoc: M1 Kliniken AG decides to start share buyback

Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

 M1 Kliniken AG decides to start share buyback

Berlin, 20 April 2023 - The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,500,000 shares of the Company in a maximum total volume of EUR 10,800,000.00 (excluding incidental acquisition costs). The resolution is based on the authorization of the Annual General Meeting of 9 July 2020 to acquire own shares. The buyback program is to start on 28 April 2023 and to be completed by the end of 26 April 2024 at the latest. The share buyback and the purchase settlement will be carried out exclusively by a credit institution or an investment firm, which will decide on the timing of the acquisition of shares independently of and without influence by the Company. The sole purpose of the share buyback program is to use the repurchased shares for all purposes provided for in the authorization resolution of the Company's Annual General Meeting of 9 July 2020 and for all other purposes permitted by the Company's share law..

The buy-back program and its implementation shall take place in compliance with the requirements of the safe harbor regulations pursuant to Art. 5 para. 2 of the Market Abuse Regulation (EU) No. 596/2014 and Art. 2, 3 and 4 of the Delegated Regulation (EU) No. 2016/1052, with the exception of the purpose of the buy-back. This is broader than determined by Art. 5 (2) of the Market Abuse Regulation.

 About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at 55 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 Group has been pushing its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia, Hungary, and Australia. With its stake in HAEMATO AG, M1 Kliniken AG is also able to exploit sales and earnings potential of treatment products in the medical-aesthetic field.